03.01.18
UNITED KINGDOM: Gallinée Ltd., a London-based, growing skin care range focusing on the skin’s microbiome, has closed its series A financing round with Unilever Ventures acting as lead investor. The investment marks Unilever Ventures’ foray into microbiome-based products, a key beauty trend in 2018.
Launched in 2016 by Marie Drago, a French pharmacist with 15 years of experience working for successful skin care brands, Gallinée was inspired by her history with autoimmune diseases and her desire to create products that support the skin’s good bacteria. Drago’s pharmacy thesis was the basis for the patented combination of probiotics, prebiotics and postbiotics that are the core of the Gallinée range.
Investment from Unilever Ventures, along with other strategic partners, will be used to develop the Gallinée team, extend the range and finance R&D. Gallinée also plans to double-down on e-commerce and expand its global direct retail operation, too.
Launched in 2016 by Marie Drago, a French pharmacist with 15 years of experience working for successful skin care brands, Gallinée was inspired by her history with autoimmune diseases and her desire to create products that support the skin’s good bacteria. Drago’s pharmacy thesis was the basis for the patented combination of probiotics, prebiotics and postbiotics that are the core of the Gallinée range.
Investment from Unilever Ventures, along with other strategic partners, will be used to develop the Gallinée team, extend the range and finance R&D. Gallinée also plans to double-down on e-commerce and expand its global direct retail operation, too.
